Resting metabolic signature of non-alcoholic fatty liver disease and the metabolic response to acute exercise in a community based sample07/01/2019 - 08/05/2022 (PI)
Doris Duke Charitable Foundation
Prevalence and risk factors for hepatic steatosis and fibrosis as measured by transient elastography03/15/2016 - 05/31/2019 (PI)
Echosens
NATiV3: A randomised, double-blind, placebo-controlled, multicentre, Phase 3 study evaluating long-term efficacy and safety of lanifibranor in adult patients with non-cirrhotic non-alcoholic steatohepatitis (NASH) and fibrosis 2 (F2)/fibrosis 3 (F3) stag05/17/2022 - 05/17/2029 (PI)
Inventiva S.A.
Global Longitudinal Assessment of Nonalcoholic Fatty Liver Disease (NAFLD) using Magnetic Resonance Elastography GOLD-MINE Study Protocol06/15/2020 - 08/03/2027 (Multi-PI)
PI:
Michelle T. Long, MD, MScThe Regents of the University of Calif., U.C. San Diego Astrazeneca Pharm
A Phase 1, Double Blind, Randomised, Placebo-controlled, Multi-centre, Multiple Ascending Dose Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AZD2693 in Patients with Non-alcoholic Steatohepatitis (NASH) with Fibrosis S12/01/2021 - 11/30/2024 (PI)
Astrazeneca Pharmaceuticals
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Phase 2a Clinical Trial to Evaluate the Safety, Tolerability, Efficacy, and Pharmacokinetics of Orally Administered TERN-101 Tablets in Adult Patients with Presumed Non-Cirrhotic09/08/2020 - 07/31/2023 (PI)
Terns Pharmaceuticals, Inc.
AURORA: A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study07/01/2019 - 07/31/2023 (PI)
Allergan Sales, LLC
MB130-06812/06/2018 - 03/31/2023 (PI)
Bristol-Myers Squibb Company
Non-alcoholic Steatohepatitis (NASH) and Stage 3 or Stage 4 Liver Fibrosis01/15/2020 - 01/14/2023 (PI)
Celgene
Identifying clinical and genetic correlates of hepatic fibrosis from fatty liver disease in the…01/12/2018 - 08/05/2022 (PI)
National Institute of Diabetes and Digestive and Kidney Diseases/NIH/DHHS5K23DK113252-03
Determining the burden, heritability, and clinical implications of increased liver stiffness from…01/02/2019 - 12/31/2021 (PI)
Gilead Sciences
MB130-06912/06/2018 - 12/06/2021 (PI)
Bristol-Myers Squibb Company
Showing 10 of 11 results.
Show All Results
A Double-Blind, Placebo-Controlled Trial of Obeticholic Acid in Patients with moderately severe A…10/06/2016 - 10/05/2018 (PI)
Indiana University NIH-NIAAA4U01AA021840-05